QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

 jmp-securities-reiterates-market-outperform-on-werewolf-therapeutics-maintains-12-price-target

JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $...

 hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

 jmp-securities-reiterates-market-outperform-on-werewolf-therapeutics-maintains-12-price-target

JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $...

 hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

 hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

 jmp-securities-reiterates-market-outperform-on-werewolf-therapeutics-maintains-12-price-target

JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $...

 hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

 werewolf-therapeutics-q1-eps-039-misses-035-estimate-sales-74200-miss-182m-estimate

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate ...

 werewolf-therapeutics-announces-wtx-124-clinical-abstract-accepted-for-presentation-at-the-2024-asco-annual-meeting

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic s...

 werewolf-therapeutics-presents-first-preclinical-data-highlighting-il-10-indukine-molecules-as-potential-therapy-for-inflammatory-bowel-disease-at-aai-annual-meeting

First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases

 werewolf-therapeutics-presents-preclinical-results-demonstrating-anti-tumor-effects-of-pro-inflammatory-cytokine-therapeutics-wtx-518-and-wtx-712-at-aacr-2024-annual-meeting

 WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regres...

 jmp-securities-initiates-coverage-on-werewolf-therapeutics-with-market-outperform-rating-announces-price-target-of-12

JMP Securities analyst Reni Benjamin initiates coverage on Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform rati...

 hc-wainwright--co-maintains-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION